4-[2-(2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoic acid:Exports & Compliance White Paper 2026

I. Executive Summary

4-[2-(2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoic acid, CAS 137281-39-1, is the pyrrolopyrimidine carboxylic acid widely known in the trade as pemetrexed acid. With the formula C15H14N4O3 and a molecular weight of about 298.30 g/mol, it combines a 7-deazaguanine-type heterocycle with a para-substituted benzoic acid connected by a two-carbon linker. It is a registered starting-material and late-stage intermediate in the manufacture of antifolate pyrrolopyrimidine active pharmaceutical ingredients, and it is handled commercially as a high-potency pharmaceutical intermediate rather than as a general fine chemical.

The material has no approved therapeutic indication of its own and is not a finished drug product. It is supplied either as a research-use-only intermediate for process development and analytical work, or as a GMP-relevant intermediate for licensed pharmaceutical manufacturers operating under their own marketing authorisations. Reputable suppliers therefore apply know-your-customer screening, collect end-use declarations, and restrict distribution to licensed pharmaceutical companies, contract manufacturers and research institutions. Nothing in this paper is dosing or therapeutic guidance.

For 2026 the decisive variable is containment and documentation capacity, not molecule availability. Demand is anchored in generic and originator antifolate API programmes, but the number of sites able to run an occupational exposure band 4 to 5 campaign with health-based exposure limit cleaning validation, ICH M7 assessment and DMF or CEP support is limited. This paper examines the structural chemistry, route classes, market, regulatory barriers, ESG profile and cold-chain logistics of the substance.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

The molecule is a compact, polyfunctional solid: a bicyclic pyrrolopyrimidine bearing a 2-amino and a 4-oxo group, a saturated ethyl bridge and a benzoic acid. The heterocycle is a deazapurine isostere presenting hydrogen-bond geometry similar to the pteridine portion of folate, while the carboxylate is both an ionisable handle for isolation and the coupling site for the amino-acid portion of the final active substance. Practical consequences include pH-dependent solubility, light and oxidative sensitivity in solution, and a solid form that must be controlled for polymorph and residual solvent.

• Deazapurine Recognition Geometry: The 2-amino-4-oxo pyrrolopyrimidine motif reproduces the donor-acceptor pattern of the pteridine ring of folate, which is why this scaffold is used in antifolate medicinal chemistry. From a manufacturing standpoint that same motif dictates handling: the compound belongs to a high-potency class that must be managed under occupational exposure band 4 to 5 containment with health-based exposure limits derived from a permitted daily exposure calculation.
• Carboxylate as the Stereochemistry-Critical Coupling Handle: The benzoic acid is activated and coupled to an enantiopure amino-acid partner in the final API step. That makes racemisation control, activation by-product control and residual coupling reagent limits part of this intermediate's quality story, and it is why buyers require a tight related-substances profile and a defined polymorphic form rather than an assay alone.

2.2 Synthesis and Manufacturing Technologies

Industrial approaches are convergent: the pyrrolopyrimidine core is assembled first, the two-carbon linker to the aromatic ring is installed by carbon-carbon bond-forming chemistry on a benzoate ester, and the ester is hydrolysed to release the acid. This paper deliberately stays at route-class level. Suppliers differentiate on purification strategy, containment, impurity control and solid-form control, and diversion-prone process detail is not provided here.

• Pyrrolopyrimidine Core Construction and Purification: The bicyclic core is built by cyclocondensation or annulation chemistry from substituted pyrimidine or pyrrole precursors, often through an alkynyl intermediate that cyclises to the pyrrole ring. Process challenges are regioisomer control, protection of the exocyclic amine, and purification. Modern campaigns replace chromatography with crystallisation wherever possible, because solvent load and operator exposure both fall when isolation is a controlled crystallisation.
• Linker Installation, Ester Hydrolysis and Metal Control: The ethyl bridge is installed by palladium-catalysed coupling to a benzoate ester, followed by reduction where an unsaturated linker is used, and finally by ester hydrolysis to the acid. Residual palladium is the critical inorganic impurity and must be controlled to ICH Q3D limits by scavenging and crystallisation, with ICP-MS release testing. Hydrolysis conditions are chosen to avoid amide or ring degradation and to deliver the specified solid form.

2.3 Core Application Matrix

• GMP Intermediate Supply for Licensed API Manufacture: The principal commercial outlet. Material is produced in dedicated or campaign GMP suites and released to licensed pharmaceutical customers for conversion to the finished active substance under their own regulatory filings. Supply agreements typically fix the route, the specification and change-control obligations.
• Research-Use-Only and Analytical Reference Use: Smaller quantities are supplied as research-use-only material for route scouting, analytical method development and validation, impurity identification, and reference-standard preparation. Such material is labelled RUO, is not intended for human or veterinary use, and is sold with end-use declaration.
• CDMO Process Development and Tech Transfer: Contract partners use the compound as a platform for demonstrating containment capability, cleaning validation, and analytical transfer. Programmes typically progress from milligram-scale route scouting through kilo-lab demonstration to a GMP campaign, with each stage adding specification and documentation requirements.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Demand follows antifolate API programmes rather than general chemical cycles. Loss of exclusivity on established antifolate actives has created a sustained generic API segment, while originator pipelines continue to consume pyrrolopyrimidine intermediates for new chemical entities and for formulation and delivery programmes. Two shifts matter commercially: buyers increasingly outsource the intermediate to contained CDMO capacity rather than building it in-house, and they increasingly require the supplier to hold or support the regulatory filing rather than simply delivering powder.

3.2 Capacity Distribution and Export Flows

Qualified capacity is concentrated in a limited number of contained sites. Chinese GMP intermediates producers in Zhejiang, Jiangsu and Shandong supply a large share of advanced intermediates, often from multipurpose plants with dedicated high-potency trains. Indian oncology API manufacturers around Hyderabad, Bengaluru and Ahmedabad combine intermediate synthesis with finished API capability and strong English-language filing support. European CDMOs in Italy, Spain, Switzerland and Germany hold the deepest experience with high-containment campaigns, CEP and DMF dossiers, and inspector expectations. Because campaigns must be scheduled around cleaning validation and changeover, lead times are governed by suite availability rather than by reactor capacity.

3.3 Market Bifurcation and Pricing Dynamics

There is effectively no spot market. Pricing is quoted per campaign and reflects containment infrastructure, suite allocation, cleaning validation, analytical release work and regulatory support, rather than raw-material cost. RUO-grade material is cheaper than GMP-released material because it omits validated cleaning, full GMP documentation and stability programmes. Buyers should compare quotations on what is included: containment band, cleaning validation, impurity methods and filing support.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

Compliance has two dimensions: pharmaceutical quality-system compliance, which governs whether the material may be used in a regulated API, and containment compliance, which governs whether the site may handle it at all. A site with an excellent GMP record but no health-based exposure limit strategy is not an acceptable source, and neither is a well-contained site without data integrity and change control.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• EU GMP, Written Confirmation and CEP Support: Material entering regulated European supply must come from a site covered by a written confirmation of GMP compliance for the specific activity, supported by EU GMP Part II expectations for active substances, and by a CEP or a customer-held DMF where applicable. Auditors will expect documented starting-material justification under ICH Q11, validated analytical methods, and stability data supporting the retest period.
• HBEL-Based Containment and Cytotoxic Waste Obligations: European expectations for shared facilities require a health-based exposure limit derived from the permitted daily exposure, with cleaning validation limits calculated from that value and from the following product's limits. Waste containing the substance is handled as cytotoxic pharmaceutical waste under national hazardous waste rules and destroyed by licensed high-temperature incineration; discharge permits and effluent monitoring are part of the site licence.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• Type II DMF and cGMP Inspection Readiness: For US-regulated supply the supplier normally supports a Type II API intermediate DMF that the customer references, and must be ready for a pre-approval inspection against 21 CFR Parts 210 and 211 expectations for active pharmaceutical ingredients. Data integrity under ALCOA principles, audit trails, and a defensible change-control history are now among the first items inspectors examine.
• Occupational Handling of Hazardous Drug Substances: North American buyers expect handling to follow hazardous-drug containment practice, including NIOSH hazardous-drug guidance and USP General Chapter 800 practice for antineoplastic agents, with closed transfer, isolator or glovebox operations, medical surveillance and documented operator training.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

High-potency pharmaceutical manufacturing is energy and solvent intensive by design: contained suites run high air-change rates with HEPA filtration, and purification has historically relied on solvent-heavy chromatography. ESG performance here is judged on solvent reduction, containment energy efficiency and cytotoxic waste destruction rather than on headline emissions.

5.1 Carbon Footprint and Circular Economy

The dominant contributors are solvent manufacture and disposal, HVAC energy for contained suites and isolators, and the energy consumed in drying and in high-temperature waste incineration. Practical abatement levers include replacing chromatographic steps with crystallisation-based purification, solvent recovery and reuse by distillation, energy recovery on incineration, and heat integration around isolation and drying. Because contained suites are the largest energy consumer, containment design and air-change management usually deliver more abatement than route changes.

5.2 Sustainable Sourcing and Traceability

Traceability here is as much about integrity of distribution as about origin. Buyers should expect batch-level records from receipt to release, complete audit trails, retain samples and reference standards, and restricted-party and end-use screening of every customer. Chain-of-custody records covering contained transfer, waste destruction and temperature form part of the same dossier and are reviewed in audits and inspections.

VI. Supply Chain Resilience and Export Logistics

The substance is a high-potency solid with limited solution stability, so logistics priorities are containment, temperature control and light protection. Shipments are small in volume but high in value, and are normally moved under qualified temperature-controlled conditions with continuous monitoring. Packaging has to keep the material dry, protected from light, and physically contained in a sealed primary container so that no operator outside a controlled environment is exposed to the powder.

6.1 Packaging Standards and Moisture/Contamination Control

• Sealed, Light-Protected, Temperature-Controlled Packing: Typical presentation is a double polyethylene bag inside an amber glass or HDPE bottle, itself packed in a fibre or steel drum with desiccant and, where stability data require it, refrigerated at 2 to 8 °C or frozen at minus 20 °C. Inert-gas closure and light protection limit oxidative and photolytic degradation.
• GMP Release Documentation and Tamper Evidence: Each lot ships with a certificate of analysis covering HPLC assay and related substances, residual solvents, palladium by ICP-MS, water, and identification by appropriate spectroscopic methods, together with a GMP statement, retest date and storage condition. Tamper-evident seals, numbered containers and retained samples support investigation without interrupting a validated campaign.

6.2 Dangerous Goods Identification and Transit Protocols

Transport classification must be confirmed against measured data for the specific grade: high-potency intermediates are sometimes assigned to Class 6.1 toxic substances or Class 9 environmentally hazardous substances, and sometimes move as non-regulated pharmaceutical solids. In all cases the powder ships sealed within a rigid secondary package under IATA, ADR or IMDG rules, with qualified temperature-controlled shippers and calibrated data loggers. Customs documentation should describe the material as a pharmaceutical intermediate for licensed industrial use, accompanied by end-use declaration to prevent diversion.

VII. Enterprise Global Expansion Strategy Guide

In this segment market access is earned through capability and evidence. The three investments below are the ones that determine whether a supplier is invited into an antifolate programme at all.

1. Build Verified High-Containment Capability: Invest in occupational exposure band 4 to 5 suites, isolator-based charging and milling, closed transfer, and a documented health-based exposure limit with cleaning validation. Publish the containment concept to customers: it is the first filter in supplier selection, ahead of price.
2. Own the Regulatory and Impurity Package: Support a DMF or CEP, maintain validated impurity methods including genotoxic-impurity and nitrosamine risk assessment, and lock the solid form. A supplier that can answer an authority's questions without involving the customer becomes structurally difficult to replace.
3. Restrict and Deepen the Customer Base: Apply know-your-customer screening, end-use declaration and restricted-party checks, and concentrate on multi-year campaign partnerships with licensed manufacturers. Dual sourcing here means qualifying a second contained site, not broadening distribution into uncontrolled channels.

VIII. Conclusion

Pemetrexed acid is a high-value, high-responsibility intermediate. Commercial success in 2026 depends less on synthetic elegance than on the ability to run a contained, validated, auditable campaign and to support a customer's regulatory filing with credible impurity, elemental and solid-form data. Suppliers who can demonstrate all of that will find demand durable, because antifolate API programmes continue to be a stable segment of the oncology supply chain and because qualified contained capacity remains scarce.

Licensed buyers should qualify on containment and documentation first, and on price second. Insist on a health-based exposure limit with validated cleaning, an ICH M7 assessment with purge justification, Q3D and Q3C data, a locked solid form, GDP-compliant cold-chain packaging with monitoring, and end-use control on every shipment. Treated that way, this intermediate is a manageable, auditable input; treated as a commodity powder, it is a fast route to a regulatory finding.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global 4-[2-(2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoic acid Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global 4-[2-(2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoic acid supply chain:

• China: Scale-Up-Oriented GMP Intermediates Plants: Producers in Zhejiang, Jiangsu and Shandong run multipurpose GMP plants with dedicated high-potency trains, offering route scouting through kilo-lab to commercial campaigns. Their strength is speed and cost at scale, and the leading sites now support DMF packages and Q3D and Q3C data.
• India: Oncology API Integration and Filing Support: Manufacturers around Hyderabad, Bengaluru and Ahmedabad combine pyrrolopyrimidine intermediate synthesis with finished oncology API capability and English-language regulatory documentation. They are often chosen where the customer wants one partner to carry the material into the filing.
• European Union: High-Containment CDMO Experience: Italian, Spanish, Swiss and German CDMOs hold the deepest experience with occupational exposure band 4 to 5 campaigns, health-based exposure limit derivation, CEP and DMF dossiers, and authority inspections. Capacity is expensive and tightly scheduled, but it is the reference standard for containment and documentation practice.